DOI: 10.36347/sasjs.2021.v07i07.007

Pages: 387-392

Background: Thyroid carcinoma, in most cases, presents clinically as a solitary nodule or as a dominant nodule within a multinodular thyroid gland. Higher serum TSH levels have been found associated with advanced stages of thyroid cancer. Objective: The aim of the study was Association of Thyroid Stimulating Hormone (TSH) with Thyroid Carcinoma. Methods: This cross-sectional study was conducted at the Department of surgery and ENT, Sir Salimullah Medical College and Midford Hospital, Dhaka, Bangladesh from the period of July 2012 to June 2014. A total of 116 patients were included for the study according to following inclusion and exclusion criteria. Other necessary investigations were done if clinically indicated. Statistical analysis of the results was obtained by using window-based computer software devised with Statistical Packages for Social Sciences (SPSS-24). Results: Out of 116 patients; 30 (25.9%) patients were 15 to 30 years of age, 53 (45.7%) were 31 to 45 years old, 29 (25%) were 46 to 60 years old and only 4 (3.4%) were 61 to 75 years old. The highest patients were belonging to 31 to 45 years age group. The mean age of the patients was 39.5 years. Majority (81.9%) of the patients was female and the rest (18.1%) were male. The most common tumor size was found to be around 2 to 4 cm (28), >4 cm (15) and <2 cm (15) respectively. Majority of the patients 68.1 % were suffering from benign tumor and 12.9% were suffering from malignant tumor. Majority patients with benign and papillary carcinoma had TSH level of 0.1 to 2 mlU/L. Conclusion: Patients with elevated TSH levels are more likely to experience differentiated carcinoma than people with low TSH levels. To generalize these results linking the differences in TSH levels between differentiated thyroid carcinoma and benign thyroid enlargement, multicenter hospital population-based studies are required.